Compare Ganges Securitie with Similar Stocks
Dashboard
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 1.01%
- Poor long term growth as Net Sales has grown by an annual rate of -0.33% and Operating profit at -25.70%
Negative results in Dec 25
With ROE of 0.2, it has a Very Expensive valuation with a 0.2 Price to Book Value
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
Ganges Securitie for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Ganges Securities Ltd Falls to 52-Week Low of Rs 103.5 as Sell-Off Deepens
For the second consecutive session, Ganges Securities Ltd has succumbed to selling pressure, hitting a fresh 52-week low of Rs 103.5 on 30 Mar 2026. This decline extends the stock’s recent losing streak, with a cumulative fall of 6.38% over two days, signalling sustained investor caution despite a sector that has also seen weakness.
Read full news article
Ganges Securities Ltd is Rated Strong Sell
Ganges Securities Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read full news article
Markets Rally, But Ganges Securities Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off
Despite a buoyant market backdrop, Ganges Securities Ltd has plunged to a fresh 52-week low of Rs 104.7 on 25 Mar 2026, marking a 27.94% decline over the past year and underperforming the Sensex by a wide margin.
Read full news article Announcements 
Closure of Trading Window
27-Mar-2026 | Source : BSEClosure of Trading window
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)
20-Mar-2026 | Source : BSEDisclosure under Regulation 30
Announcement under Regulation 30 (LODR)-Newspaper Publication
12-Feb-2026 | Source : BSENewspaper publication
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 1 Schemes (0.01%)
Held by 1 FIIs (0.03%)
Sil Investments Limited (13.38%)
Navjeewan Medical Institute (6.21%)
21.88%
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
YoY Growth in quarter ended Dec 2025 is -14.20% vs 1.00% in Dec 2024
YoY Growth in quarter ended Dec 2025 is 82.50% vs -40.30% in Dec 2024
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -4.41% vs 19.10% in Sep 2024
Growth in half year ended Sep 2025 is -52.87% vs 35.93% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -7.98% vs 11.81% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -41.05% vs 22.30% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 9.08% vs -15.57% in Mar 2024
YoY Growth in year ended Mar 2025 is 45.40% vs -64.31% in Mar 2024






